Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17693380rdf:typepubmed:Citationlld:pubmed
pubmed-article:17693380lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17693380lifeskim:mentionsumls-concept:C0239307lld:lifeskim
pubmed-article:17693380lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:17693380lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:17693380lifeskim:mentionsumls-concept:C0001645lld:lifeskim
pubmed-article:17693380lifeskim:mentionsumls-concept:C0025859lld:lifeskim
pubmed-article:17693380lifeskim:mentionsumls-concept:C0054836lld:lifeskim
pubmed-article:17693380lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:17693380lifeskim:mentionsumls-concept:C0264716lld:lifeskim
pubmed-article:17693380lifeskim:mentionsumls-concept:C1417808lld:lifeskim
pubmed-article:17693380lifeskim:mentionsumls-concept:C1095989lld:lifeskim
pubmed-article:17693380lifeskim:mentionsumls-concept:C0220901lld:lifeskim
pubmed-article:17693380lifeskim:mentionsumls-concept:C2347828lld:lifeskim
pubmed-article:17693380lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:17693380pubmed:issue8lld:pubmed
pubmed-article:17693380pubmed:dateCreated2007-8-13lld:pubmed
pubmed-article:17693380pubmed:abstractTextPlasma levels of N-terminal pro-brain natriuretic peptide (NT-pro BNP) are increased in patients with chronic heart failure (CHF). Beta-blockers (BB) may influence these levels but it is unclear whether changes in NT-pro BNP reflect concomitant changes in prognosis.lld:pubmed
pubmed-article:17693380pubmed:languageenglld:pubmed
pubmed-article:17693380pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17693380pubmed:citationSubsetIMlld:pubmed
pubmed-article:17693380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17693380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17693380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17693380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17693380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17693380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17693380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17693380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17693380pubmed:statusMEDLINElld:pubmed
pubmed-article:17693380pubmed:monthAuglld:pubmed
pubmed-article:17693380pubmed:issn1388-9842lld:pubmed
pubmed-article:17693380pubmed:authorpubmed-author:ClelandJohn...lld:pubmed
pubmed-article:17693380pubmed:authorpubmed-author:RemmeWillem...lld:pubmed
pubmed-article:17693380pubmed:authorpubmed-author:SwedbergKarlKlld:pubmed
pubmed-article:17693380pubmed:authorpubmed-author:Torp-Pedersen...lld:pubmed
pubmed-article:17693380pubmed:authorpubmed-author:MetraMarcoMlld:pubmed
pubmed-article:17693380pubmed:authorpubmed-author:KomajdaMichel...lld:pubmed
pubmed-article:17693380pubmed:authorpubmed-author:Poole-WilsonP...lld:pubmed
pubmed-article:17693380pubmed:authorpubmed-author:ScherhagArmin...lld:pubmed
pubmed-article:17693380pubmed:authorpubmed-author:OlssonLars...lld:pubmed
pubmed-article:17693380pubmed:authorpubmed-author:COMET...lld:pubmed
pubmed-article:17693380pubmed:authorpubmed-author:SparkPhillip...lld:pubmed
pubmed-article:17693380pubmed:issnTypePrintlld:pubmed
pubmed-article:17693380pubmed:volume9lld:pubmed
pubmed-article:17693380pubmed:ownerNLMlld:pubmed
pubmed-article:17693380pubmed:authorsCompleteYlld:pubmed
pubmed-article:17693380pubmed:pagination795-801lld:pubmed
pubmed-article:17693380pubmed:dateRevised2011-6-8lld:pubmed
pubmed-article:17693380pubmed:meshHeadingpubmed-meshheading:17693380...lld:pubmed
pubmed-article:17693380pubmed:meshHeadingpubmed-meshheading:17693380...lld:pubmed
pubmed-article:17693380pubmed:meshHeadingpubmed-meshheading:17693380...lld:pubmed
pubmed-article:17693380pubmed:meshHeadingpubmed-meshheading:17693380...lld:pubmed
pubmed-article:17693380pubmed:meshHeadingpubmed-meshheading:17693380...lld:pubmed
pubmed-article:17693380pubmed:meshHeadingpubmed-meshheading:17693380...lld:pubmed
pubmed-article:17693380pubmed:meshHeadingpubmed-meshheading:17693380...lld:pubmed
pubmed-article:17693380pubmed:meshHeadingpubmed-meshheading:17693380...lld:pubmed
pubmed-article:17693380pubmed:meshHeadingpubmed-meshheading:17693380...lld:pubmed
pubmed-article:17693380pubmed:meshHeadingpubmed-meshheading:17693380...lld:pubmed
pubmed-article:17693380pubmed:meshHeadingpubmed-meshheading:17693380...lld:pubmed
pubmed-article:17693380pubmed:meshHeadingpubmed-meshheading:17693380...lld:pubmed
pubmed-article:17693380pubmed:meshHeadingpubmed-meshheading:17693380...lld:pubmed
pubmed-article:17693380pubmed:meshHeadingpubmed-meshheading:17693380...lld:pubmed
pubmed-article:17693380pubmed:year2007lld:pubmed
pubmed-article:17693380pubmed:articleTitlePrognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.lld:pubmed
pubmed-article:17693380pubmed:affiliationDepartment of Emergency and Cardiovascular Medicine Sahlgrenska Academy, Göteborg University, Göteborg, Sweden, and Department of Cardiology, La Pitié-Salpétrière Hospital, Paris, France.lld:pubmed
pubmed-article:17693380pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17693380pubmed:publicationTypeRandomized Controlled Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17693380lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17693380lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17693380lld:pubmed